enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco ...

   lite.aol.com/tech/story/0022/20241204/9314424.htm

   BIZENGRI ® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic 1 Merus and Partner Therapeutics announced a license agreement for U.S. commercialization

3. Immuneering Granted Orphan Drug Designation for IMM-1-104 by ...

   lite.aol.com/tech/story/0022/20241015/9255874.htm

   “The FDA’s granting of orphan drug designation for IMM-1-104 underscores the urgent need for new therapies that meaningfully improve outcomes for pancreatic cancer patients and represents an important milestone in the development of our lead asset,” said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering.

4. Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

   www.aol.com/news/syros-syrs-fdas-orphan-tag...

   Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

5. AstraZeneca, Merck score win with Lynparza approval for ... - AOL

   www.aol.com/news/astrazeneca-merck-score-win...

   AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer ...

6. Bi-specific T-cell engager - Wikipedia

   en.wikipedia.org/wiki/Bi-specific_T-cell_engager

   Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.

7. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

8. Gemcitabine - Wikipedia

   en.wikipedia.org/wiki/Gemcitabine

   The pancreatic cancer trials found that gemcitabine increased one-year survival rate significantly, and it was approved in the UK in 1995 [11] and approved by the FDA in 1996 for pancreatic cancers. [5] In 1998, gemcitabine received FDA approval for treating non-small cell lung cancer and in 2004, it was approved for metastatic breast cancer. [5]

9. FDA approves drug for treating pancreatic cancer - AOL

   www.aol.com/news/fda-approves-drug-treating...

   For premium support please call: 800-290-4726 more ways to reach us